A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 883-892

  Antonarakis, Emmanuel S ^a   Heath, Elisabeth I ^b   Posadas, Edwin M ^c   Yu, Evan Y ^d   Harrison, Michael R ^e   Bruce, Justine Y ^f   Cho, Steve Y ^a   Wilding, Gregory E ^g   Fetterly, Gerald J ^h   Hangauer, David G ⁱ   Kwan, Min Fun R ⁱ   Dyster, Lyn M ⁱ   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e DUKE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ Kinex Pharmaceuticals LLC   (United States)

Author keywords

KX2 391; Prostate cancer; Src inhibitor; Tubulin polymerization

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANTINEOPLASTIC AGENT; CARBOXY TERMINAL TELOPEPTIDE; KX 2 391; OSTEOCALCIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; N BENZYL 2 (5 (4 (2 MORPHOLINOETHOXY)PHENYL)PYRIDIN 2 YL)ACETAMIDE; N-BENZYL-2-(5-(4-(2-MORPHOLINOETHOXY)PHENYL)PYRIDIN-2-YL)ACETAMIDE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; TUBULIN MODULATOR;

ADULT; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BONE METABOLISM; BONE METASTASIS; BONE PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOTHERAPY INDUCED ANEMIA; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HUMAN CELL; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; BONE; BONE TUMOR; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PATHOLOGY; PROSTATE TUMOR; TUMOR EMBOLISM; VERY ELDERLY;

ACETAMIDES; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; ORCHIECTOMY; PROSTATIC NEOPLASMS; PYRIDINES; SRC-FAMILY KINASES; TUBULIN MODULATORS;

MLCS; MLOWN;

EID: 84878871141     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2079-z     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
2. Antonarakis ES, Eisenberger MA (2011) Expanding treatment options for metastatic prostate cancer. N Engl J Med 364:2055-2058
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
4. Chang YM, Kung HJ, Evans CP (2007) Non-receptor tyrosine kinases in prostate cancer. Neoplasia 9:90-100
5. Posadas EM, Al-Ahmadie H, Robinson VL et al (2009) FYN is overexpressed in human prostate cancer. BJU Int 103:171-177
6. Fizazi K (2007) The role of Src in prostate cancer. Ann Oncol 18:1765-1773 (Pubitemid 350119560)
7. Araujo JC, Logothetis CJ (2009) Targeting Src signaling in metastatic bone disease. Int J Cancer 124:1-6
8. Tatarov O, Mitchell TJ, Seywright M et al (2009) Src family kinase activity is upregulated in hormone-refractory prostate cancer. Clin Cancer Res 15:3540-3549
9. Yu EY, Wilding G, Posadas E et al (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421-7428
10. Araujo JC, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118:63-71
11. Fallah-Tafti A, Foroumadi A, Tiwari R et al (2011) Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem 46:4853-4858
12. Hangauer D, Gelman I, Dyster L et al (2007) Potent and selective in vitro and in vivo inhibition of tumor proliferation by KXO1, a novel non-ATP competitive Src inhibitor. Proc Am Assoc Cancer Res 2007: abstract 3245
13. Bu Y, Gao L, Smolinski M et al (2008) KX01 (KX2-391), a Src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Proc Am Assoc Cancer Res 2008: abstract 4983
14. Adjei AA, Cohen RB, Kurzrock R et al (2009) Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed Src inhibitor, in patients with advanced malignancies. J Clin Oncol 27(Suppl): abstract 3511
15. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
16. Morris MJ, Basch EM, Wilding G et al (2009) Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer 7:51-57
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
18. Shaffer DR, Leversha MA, Danila DC et al (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:2023-2029 (Pubitemid 46649868)
19. Franke RM, Carducci MA, Rudek MA et al (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562-4567
20. Fizazi K, Lipton A, Mariette X et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571
21. Carducci MA, Saad F, Abrahamsson PA et al (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959-1966 (Pubitemid 350036854)
22. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10 (Pubitemid 19099520)
23. Lara PN Jr, Longmate J, Evans CP et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20:179-184
24. Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201 (Pubitemid 351976401)
25. Yu EY, Massard C, Gross ME et al (2011) Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 77:1166-1171